Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-12
2011-04-12
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S044000, C514S420000, C514S568000, C424S474000, C424S468000
Reexamination Certificate
active
07923453
ABSTRACT:
A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.
REFERENCES:
patent: 6310072 (2001-10-01), Smith et al.
patent: 2005/0053659 (2005-03-01), Pace et al.
patent: 2008/0039463 (2008-02-01), Nadeson et al.
patent: 2009/0291975 (2009-11-01), Stern et al.
patent: 2010/085848 (2010-08-01), None
Kerri Wachter (Internal Medicine News, 2008).
McPherson (Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing, Publication date Aug. 25, 2009).
Alberta Hospice document (Alberta Hospice Palliative Care Resource Manual 2001).
Embeda® Prescribing Information, Jun. 2009.
Morphine Sulfate Prescribing Information, Mar. 2008.
Oxycontin® Prescribing Information, Apr. 16, 2010.
Opana® Prescribing Information, 2006.
Chevlen E.,J. Pain Symptom. Manag., 19:1 (2000) S42-9.
Ross et al.,Pain84 (2000) 421-28.
Riley et al.,Eur. J. Pain Suppl., 1 (2007) 23-30.
Riley et al.,Support Care Cancer14 (2006) 56-64.
Mercadante et al.,Cancer, 95 (2002) 203-08.
Mercadante el al.,Cancer Treatment Reviews32 (2006) 304-15.
Mercadante, S.,Eur. J. Pain11 (2007) 823-30.
Holaday et al.,Perioperative Medizin, 1:4 (2009) 244.
Kotlinska-Lemieszek , A.,J. Pain Symptom. Manag., 40:1 (2010) e10-e12.
Ladd et al.,Br. J. Clin. Pharmacol., 59:5 (2005) 524-35.
Grach et al.,Br. J. Clin. Pharmacol., 58:3 (2004) 235-42.
Smith et al.,Br. J. Clin. Pharmacol., 59:4 (2005) 486-87.
Anderson et al.,J. Pain Symptom Manage., 21:5 (2001) 397-406 (“Anderson”).
Lichtor et al.,Anesth. Analg., 89 (1999) 732-38.
Foley, K.,N. Engl. J. Med., 313:2 (1985) 84-95.
Richards et al.,J. Pain10:4 (2009) S49; Richards et al.,Two Exploratory Double-Blinded Crossover Studies of the Treatment of Chronic Noncancer Pain: Efficacy and Safety of Concurrent Dosing of Morphine Plus Oxycodone vs Morphine Alone, 2009 Annual Meeting of the America Pain Society, May 7-9, 2009, San Diego, CA.
Webster et al.,J. Pain11:4 (2010) S50.
Webster et al.,J. Pain11:4 (2010) S51.
Webster et al.,J. Pain11:4 (2010) S53.
Webster et al.,Single-Dose and Steady-State Pharmacokinetics of MaxDuo®, a Dual Opioid Formulation Containing a Fixed Ratio of Morphine and Oxycodone, 29thAnnual Meeting of the America Pain Society, May 6-8, 2010, Baltimore, MD.
www.palliative.org/PC/ClinicalInfo/AssessmentTools/MeanEquivalent%20for%20program%20v3.pdf, Jul. 26, 2010.
www.QRxPharma.com, Press Release, Sep. 1, 2010.
www.QRxPharma.com, Press Release, Aug. 17, 2010.
www.QRxPharrna com, Press Release, May 4, 2010.
www.QRxPharma.com, Press Release, Apr. 14, 2010.
www.QRxPharma.com, Press Release, Mar. 30, 2010.
www.QRxPharma.com, Press Release, Feb. 10, 2010.
www.QRxPharma.com, Press Release, Nov. 30, 2009.
www.QRxPharma.com, Press Release, Aug. 26, 2009.
www.QRxPharma.com, Press Release, Apr. 20, 2009.
www.QRxPharma.com, Press Release, May 22, 2008.
www.QRxPharma.com, Press Release, May 5, 2008.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, Patent Cooperation Treaty, Dec. 30, 2009, PCT/US09/62917.
Mengle-Gaw Laurel J.
Richards Patricia T.
Schwartz Benjamin D.
Stern Warren C.
Frommer & Lawrence & Haug LLP
Garman Russell A.
Kuzmich Sandra
Padmanabhan Sreeni
QRxPharma Ltd.
LandOfFree
Methods of converting a patient's treatment regimen from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of converting a patient's treatment regimen from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of converting a patient's treatment regimen from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670659